The objective of this US-based retrospective cohort study is to evaluate characteristics, vaccine utilization and outcomes among subjects with immunocompromising conditions that received COVID-19 vaccination.~Subjects will be aged 12 years and older and will have no evidence of prior SARS-CoV-2 infection.~The primary analysis will be conducted on subjects vaccinated with BNT162b2.~A variety of subgroup analyses and sensitivity analyses are planned.
This retrospective study will evaluate characteristics, vaccine utilization and outcomes among subjects with immunocompromising conditions that received COVID-19 vaccination.